Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2005

Open Access 01-12-2005 | Review

Oxidative stress and the use of antioxidants in diabetes: Linking basic science to clinical practice

Authors: Jeanette Schultz Johansen, Alex K Harris, David J Rychly, Adviye Ergul

Published in: Cardiovascular Diabetology | Issue 1/2005

Login to get access

Abstract

Cardiovascular complications, characterized by endothelial dysfunction and accelerated atherosclerosis, are the leading cause of morbidity and mortality associated with diabetes. There is growing evidence that excess generation of highly reactive free radicals, largely due to hyperglycemia, causes oxidative stress, which further exacerbates the development and progression of diabetes and its complications. Overproduction and/or insufficient removal of these free radicals result in vascular dysfunction, damage to cellular proteins, membrane lipids and nucleic acids. Despite overwhelming evidence on the damaging consequences of oxidative stress and its role in experimental diabetes, large scale clinical trials with classic antioxidants failed to demonstrate any benefit for diabetic patients. As our understanding of the mechanisms of free radical generation evolves, it is becoming clear that rather than merely scavenging reactive radicals, a more comprehensive approach aimed at preventing the generation of these reactive species as well as scavenging may prove more beneficial. Therefore, new strategies with classic as well as new antioxidants should be implemented in the treatment of diabetes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pyorala K, Laakso M, Uusitupa M: Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987, 3 (2): 463-524.CrossRefPubMed Pyorala K, Laakso M, Uusitupa M: Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987, 3 (2): 463-524.CrossRefPubMed
2.
go back to reference Laakso M: Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999, 48 (5): 937-942.CrossRefPubMed Laakso M: Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999, 48 (5): 937-942.CrossRefPubMed
4.
go back to reference The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993, 329 (14): 977-986. 10.1056/NEJM199309303291401.CrossRef The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993, 329 (14): 977-986. 10.1056/NEJM199309303291401.CrossRef
5.
go back to reference Giugliano D, Ceriello A, Paolisso G: Oxidative stress and diabetic vascular complications. Diabetes Care. 1996, 19 (3): 257-267.CrossRefPubMed Giugliano D, Ceriello A, Paolisso G: Oxidative stress and diabetic vascular complications. Diabetes Care. 1996, 19 (3): 257-267.CrossRefPubMed
6.
go back to reference Ceriello A: New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care. 2003, 26 (5): 1589-1596.CrossRefPubMed Ceriello A: New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care. 2003, 26 (5): 1589-1596.CrossRefPubMed
7.
go back to reference Ceriello A, Motz E: Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004, 24 (5): 816-823. 10.1161/01.ATV.0000122852.22604.78.CrossRefPubMed Ceriello A, Motz E: Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004, 24 (5): 816-823. 10.1161/01.ATV.0000122852.22604.78.CrossRefPubMed
8.
go back to reference Turko IV, Marcondes S, Murad F: Diabetes-associated nitration of tyrosine and inactivation of succinyl-CoA:3-oxoacid CoA-transferase. Am J Physiol Heart Circ Physiol. 2001, 281 (6): H2289-2294.PubMed Turko IV, Marcondes S, Murad F: Diabetes-associated nitration of tyrosine and inactivation of succinyl-CoA:3-oxoacid CoA-transferase. Am J Physiol Heart Circ Physiol. 2001, 281 (6): H2289-2294.PubMed
9.
go back to reference Maritim AC, Sanders RA, Watkins JB: Diabetes, oxidative stress, and antioxidants: A review. J Biochem Mol Toxicol. 2003, 17 (1): 24-38. 10.1002/jbt.10058.CrossRefPubMed Maritim AC, Sanders RA, Watkins JB: Diabetes, oxidative stress, and antioxidants: A review. J Biochem Mol Toxicol. 2003, 17 (1): 24-38. 10.1002/jbt.10058.CrossRefPubMed
10.
go back to reference Evans JL, Goldfine ID, Maddux BA, Grodsky GM: Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002, 23 (5): 599-622. 10.1210/er.2001-0039.CrossRefPubMed Evans JL, Goldfine ID, Maddux BA, Grodsky GM: Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002, 23 (5): 599-622. 10.1210/er.2001-0039.CrossRefPubMed
11.
go back to reference Vega-Lopez S, Devaraj S, Jialal I: Oxidative stress and antioxidant supplementation in the management of diabetic cardiovascular disease. J Investig Med. 2004, 52 (1): 24-32.CrossRefPubMed Vega-Lopez S, Devaraj S, Jialal I: Oxidative stress and antioxidant supplementation in the management of diabetic cardiovascular disease. J Investig Med. 2004, 52 (1): 24-32.CrossRefPubMed
12.
go back to reference Evans JL, Goldfine ID, Maddux BA, Grodsky GM: Are oxidative stress-activated signaling pathways mediators of insulin resistance and {beta}-cell dysfunction?. Diabetes. 2003, 52 (1): 1-8.CrossRefPubMed Evans JL, Goldfine ID, Maddux BA, Grodsky GM: Are oxidative stress-activated signaling pathways mediators of insulin resistance and {beta}-cell dysfunction?. Diabetes. 2003, 52 (1): 1-8.CrossRefPubMed
13.
go back to reference Griendling KK, FitzGerald GA: Oxidative stress and cardiovascular injury: Part I: Basic mechanisms and in vivo monitoring of ROS. Circulation. 2003, 108 (16): 1912-1916. 10.1161/01.CIR.0000093660.86242.BB.CrossRefPubMed Griendling KK, FitzGerald GA: Oxidative stress and cardiovascular injury: Part I: Basic mechanisms and in vivo monitoring of ROS. Circulation. 2003, 108 (16): 1912-1916. 10.1161/01.CIR.0000093660.86242.BB.CrossRefPubMed
14.
go back to reference Griendling KK, FitzGerald GA: Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation. 2003, 108 (17): 2034-2040. 10.1161/01.CIR.0000093661.90582.c4.CrossRefPubMed Griendling KK, FitzGerald GA: Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation. 2003, 108 (17): 2034-2040. 10.1161/01.CIR.0000093661.90582.c4.CrossRefPubMed
15.
go back to reference Taniyama Y, Griendling KK: Reactive oxygen species in the vasculature: Molecular and cellular mechanisms. Hypertension. 2003, 42 (6): 1075-1081. 10.1161/01.HYP.0000100443.09293.4F.CrossRefPubMed Taniyama Y, Griendling KK: Reactive oxygen species in the vasculature: Molecular and cellular mechanisms. Hypertension. 2003, 42 (6): 1075-1081. 10.1161/01.HYP.0000100443.09293.4F.CrossRefPubMed
16.
go back to reference Boullier A, Bird DA, Chang MK, Dennis EA, Friedman P, Gillotre-Taylor K, Horkko S, Palinski W, Quehenberger O, Shaw P: Scavenger receptors, oxidized LDL, and atherosclerosis. Ann N Y Acad Sci. 2001, 947: 214-222.CrossRefPubMed Boullier A, Bird DA, Chang MK, Dennis EA, Friedman P, Gillotre-Taylor K, Horkko S, Palinski W, Quehenberger O, Shaw P: Scavenger receptors, oxidized LDL, and atherosclerosis. Ann N Y Acad Sci. 2001, 947: 214-222.CrossRefPubMed
17.
go back to reference Liu Y, Gutterman DD: The coronary circulation in diabetes: influence of reactive oxygen species on K+ channel-mediated vasodilation. Vascul Pharmacol. 2002, 38 (1): 43-49. 10.1016/S1537-1891(02)00125-8.CrossRefPubMed Liu Y, Gutterman DD: The coronary circulation in diabetes: influence of reactive oxygen species on K+ channel-mediated vasodilation. Vascul Pharmacol. 2002, 38 (1): 43-49. 10.1016/S1537-1891(02)00125-8.CrossRefPubMed
18.
go back to reference Liu Y, Terata K, Chai Q, Li H, Kleinman LH, Gutterman DD: Peroxynitrite inhibits Ca2+-activated K+ channel activity in smooth muscle of human coronary arterioles. Circ Res. 2002, 91 (11): 1070-1076. 10.1161/01.RES.0000046003.14031.98.CrossRefPubMed Liu Y, Terata K, Chai Q, Li H, Kleinman LH, Gutterman DD: Peroxynitrite inhibits Ca2+-activated K+ channel activity in smooth muscle of human coronary arterioles. Circ Res. 2002, 91 (11): 1070-1076. 10.1161/01.RES.0000046003.14031.98.CrossRefPubMed
19.
go back to reference Soriano FG, Virag L, Szabo C: Diabetic endothelial dysfunction: role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation. J Mol Med. 2001, 79 (8): 437-448. 10.1007/s001090100236.CrossRefPubMed Soriano FG, Virag L, Szabo C: Diabetic endothelial dysfunction: role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation. J Mol Med. 2001, 79 (8): 437-448. 10.1007/s001090100236.CrossRefPubMed
20.
go back to reference Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J: Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004, 65 (3): 1009-1016. 10.1111/j.1523-1755.2004.00465.x.CrossRefPubMed Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J: Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004, 65 (3): 1009-1016. 10.1111/j.1523-1755.2004.00465.x.CrossRefPubMed
21.
go back to reference Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, Channon KM: Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res. 2000, 86 (9): E85-90.CrossRefPubMed Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, Channon KM: Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res. 2000, 86 (9): E85-90.CrossRefPubMed
22.
go back to reference Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM: Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation. 2002, 105 (14): 1656-1662. 10.1161/01.CIR.0000012748.58444.08.CrossRefPubMed Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM: Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation. 2002, 105 (14): 1656-1662. 10.1161/01.CIR.0000012748.58444.08.CrossRefPubMed
23.
go back to reference Ceriello A, Mercuri F, Quagliaro L, Assaloni R, Motz E, Tonutti L, Taboga C: Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia. 2001, 44 (7): 834-838. 10.1007/s001250100529.CrossRefPubMed Ceriello A, Mercuri F, Quagliaro L, Assaloni R, Motz E, Tonutti L, Taboga C: Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia. 2001, 44 (7): 834-838. 10.1007/s001250100529.CrossRefPubMed
24.
go back to reference Aliciguzel Y, Ozen I, Aslan M, Karayalcin U: Activities of xanthine oxidoreductase and antioxidant enzymes in different tissues of diabetic rats. J Lab Clin Med. 2003, 142 (3): 172-177. 10.1016/S0022-2143(03)00110-0.CrossRefPubMed Aliciguzel Y, Ozen I, Aslan M, Karayalcin U: Activities of xanthine oxidoreductase and antioxidant enzymes in different tissues of diabetic rats. J Lab Clin Med. 2003, 142 (3): 172-177. 10.1016/S0022-2143(03)00110-0.CrossRefPubMed
25.
go back to reference Kitada M, Koya D, Sugimoto T, Isono M, Araki S, Kashiwagi A, Haneda M: Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes. 2003, 52 (10): 2603-2614.CrossRefPubMed Kitada M, Koya D, Sugimoto T, Isono M, Araki S, Kashiwagi A, Haneda M: Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes. 2003, 52 (10): 2603-2614.CrossRefPubMed
26.
go back to reference Etoh T, Inoguchi T, Kakimoto M, Sonoda N, Kobayashi K, Kuroda J, Sumimoto H, Nawata H: Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment. Diabetologia. 2003, 46 (10): 1428-1437. 10.1007/s00125-003-1205-6.CrossRefPubMed Etoh T, Inoguchi T, Kakimoto M, Sonoda N, Kobayashi K, Kuroda J, Sumimoto H, Nawata H: Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment. Diabetologia. 2003, 46 (10): 1428-1437. 10.1007/s00125-003-1205-6.CrossRefPubMed
27.
go back to reference Ergul A, Schultz Johansen J, Stromhaug C, Harris AK, Hutchinson J, Tawfik A, Rahimi A, Rhim E, Wells B, Caldwell RW: Vascular dysfunction of venous bypass conduits is mediated by reactive oxygen species in diabetes: Role of endothelin-1. J Pharmacol Exp Ther. 2004, 313: 70-77. 10.1124/jpet.104.078105.CrossRefPubMed Ergul A, Schultz Johansen J, Stromhaug C, Harris AK, Hutchinson J, Tawfik A, Rahimi A, Rhim E, Wells B, Caldwell RW: Vascular dysfunction of venous bypass conduits is mediated by reactive oxygen species in diabetes: Role of endothelin-1. J Pharmacol Exp Ther. 2004, 313: 70-77. 10.1124/jpet.104.078105.CrossRefPubMed
28.
go back to reference Amiri F, Shaw S, Wang X, Tang J, Waller JL, Eaton DC, Marrero MB: Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose. Kidney Int. 2002, 61 (5): 1605-1616. 10.1046/j.1523-1755.2002.00311.x.CrossRefPubMed Amiri F, Shaw S, Wang X, Tang J, Waller JL, Eaton DC, Marrero MB: Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose. Kidney Int. 2002, 61 (5): 1605-1616. 10.1046/j.1523-1755.2002.00311.x.CrossRefPubMed
29.
go back to reference Green K, Brand MD, Murphy MP: Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes. 2004, 53 (Suppl 1): S110-118.CrossRefPubMed Green K, Brand MD, Murphy MP: Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes. 2004, 53 (Suppl 1): S110-118.CrossRefPubMed
30.
go back to reference Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000, 404 (6779): 787-790. 10.1038/35008121.CrossRefPubMed Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000, 404 (6779): 787-790. 10.1038/35008121.CrossRefPubMed
31.
go back to reference Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature. 2001, 414 (6865): 813-820. 10.1038/414813a.CrossRefPubMed Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature. 2001, 414 (6865): 813-820. 10.1038/414813a.CrossRefPubMed
32.
go back to reference Kaul N, Siveski-Iliskovic N, Hill M, Khaper N, Seneviratne C, Singal PK: Probucol treatment reverses antioxidant and functional deficit in diabetic cardiomyopathy. Mol Cell Biochem. 1996, 160–161: 283-288. 10.1007/BF00240060.CrossRefPubMed Kaul N, Siveski-Iliskovic N, Hill M, Khaper N, Seneviratne C, Singal PK: Probucol treatment reverses antioxidant and functional deficit in diabetic cardiomyopathy. Mol Cell Biochem. 1996, 160–161: 283-288. 10.1007/BF00240060.CrossRefPubMed
33.
go back to reference Hayden MR, Tyagi SC: Myocardial redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and congestive heart failure. Med Sci Monit. 2003, 9 (7): SR35-52.PubMed Hayden MR, Tyagi SC: Myocardial redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and congestive heart failure. Med Sci Monit. 2003, 9 (7): SR35-52.PubMed
34.
go back to reference Linke A, Adams V, Schulze PC, Erbs S, Gielen S, Fiehn E, Mobius-Winkler S, Schubert A, Schuler G, Hambrecht R: Antioxidative effects of exercise training in patients with chronic heart failure: increase in radical scavenger enzyme activity in skeletal muscle. Circulation. 2005, 111 (14): 1763-1770. 10.1161/01.CIR.0000165503.08661.E5.CrossRefPubMed Linke A, Adams V, Schulze PC, Erbs S, Gielen S, Fiehn E, Mobius-Winkler S, Schubert A, Schuler G, Hambrecht R: Antioxidative effects of exercise training in patients with chronic heart failure: increase in radical scavenger enzyme activity in skeletal muscle. Circulation. 2005, 111 (14): 1763-1770. 10.1161/01.CIR.0000165503.08661.E5.CrossRefPubMed
35.
go back to reference Cristina Polidori M, Pratico D, Savino K, Rokach J, Stahl W, Mecocci P: Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity. J Card Fail. 2004, 10 (4): 334-338. 10.1016/j.cardfail.2003.11.004.CrossRefPubMed Cristina Polidori M, Pratico D, Savino K, Rokach J, Stahl W, Mecocci P: Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity. J Card Fail. 2004, 10 (4): 334-338. 10.1016/j.cardfail.2003.11.004.CrossRefPubMed
36.
go back to reference Hensley K, Robinson KA, Gabbita SP, Salsman S, Floyd RA: Reactive oxygen species, cell signaling, and cell injury. Free Radic Biol Med. 2000, 28 (10): 1456-1462. 10.1016/S0891-5849(00)00252-5.CrossRefPubMed Hensley K, Robinson KA, Gabbita SP, Salsman S, Floyd RA: Reactive oxygen species, cell signaling, and cell injury. Free Radic Biol Med. 2000, 28 (10): 1456-1462. 10.1016/S0891-5849(00)00252-5.CrossRefPubMed
37.
go back to reference Hensley K, Benaksas EJ, Bolli R, Comp P, Grammas P, Hamdheydari L, Mou S, Pye QN, Stoddard MF, Wallis G: New perspectives on vitamin E: gamma-tocopherol and carboxyelthylhydroxychroman metabolites in biology and medicine. Free Radic Biol Med. 2004, 36 (1): 1-15. 10.1016/j.freeradbiomed.2003.10.009.CrossRefPubMed Hensley K, Benaksas EJ, Bolli R, Comp P, Grammas P, Hamdheydari L, Mou S, Pye QN, Stoddard MF, Wallis G: New perspectives on vitamin E: gamma-tocopherol and carboxyelthylhydroxychroman metabolites in biology and medicine. Free Radic Biol Med. 2004, 36 (1): 1-15. 10.1016/j.freeradbiomed.2003.10.009.CrossRefPubMed
38.
go back to reference Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD: Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr. 2002, 56 (11): 1137-1142. 10.1038/sj.ejcn.1601464.CrossRefPubMed Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD: Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr. 2002, 56 (11): 1137-1142. 10.1038/sj.ejcn.1601464.CrossRefPubMed
39.
go back to reference Hodgson JM, Watts GF: Can coenzyme Q10 improve vascular function and blood pressure? Potential for effective therapeutic reduction in vascular oxidative stress. Biofactors. 2003, 18 (1–4): 129-136.CrossRefPubMed Hodgson JM, Watts GF: Can coenzyme Q10 improve vascular function and blood pressure? Potential for effective therapeutic reduction in vascular oxidative stress. Biofactors. 2003, 18 (1–4): 129-136.CrossRefPubMed
40.
go back to reference Watts GF, Playford DA, Croft KD, Ward NC, Mori TA, Burke V: Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia. 2002, 45 (3): 420-426. 10.1007/s00125-001-0760-y.CrossRefPubMed Watts GF, Playford DA, Croft KD, Ward NC, Mori TA, Burke V: Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia. 2002, 45 (3): 420-426. 10.1007/s00125-001-0760-y.CrossRefPubMed
41.
go back to reference Heller R, Unbehaun A, Schellenberg B, Mayer B, Werner-Felmayer G, Werner ER: L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem. 2001, 276 (1): 40-47. 10.1074/jbc.M004392200.CrossRefPubMed Heller R, Unbehaun A, Schellenberg B, Mayer B, Werner-Felmayer G, Werner ER: L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem. 2001, 276 (1): 40-47. 10.1074/jbc.M004392200.CrossRefPubMed
42.
go back to reference Mekinova D, Chorvathova V, Volkovova K, Staruchova M, Grancicova E, Klvanoca J, Ondreicka R: Effect of intake of exogenous vitamins C, E and beta-carotene on the antioxidative status in kidneys of rats with streptozotocin-induced diabetes. Nahrung. 1995, 39 (4): 257-261.CrossRefPubMed Mekinova D, Chorvathova V, Volkovova K, Staruchova M, Grancicova E, Klvanoca J, Ondreicka R: Effect of intake of exogenous vitamins C, E and beta-carotene on the antioxidative status in kidneys of rats with streptozotocin-induced diabetes. Nahrung. 1995, 39 (4): 257-261.CrossRefPubMed
43.
go back to reference Kedziora-kornatowska K, Szram S, Kornatowski T, Szadujkis-Szadurski L, Kedziora J, Bartosz G: Effect of vitamin E and vitamin C supplementation of antioxidative state and renal glomerular basement membrane thickness in diabetic kidney. Exp Nephrology. 2003, 95: 134-143. 10.1159/000074840.CrossRef Kedziora-kornatowska K, Szram S, Kornatowski T, Szadujkis-Szadurski L, Kedziora J, Bartosz G: Effect of vitamin E and vitamin C supplementation of antioxidative state and renal glomerular basement membrane thickness in diabetic kidney. Exp Nephrology. 2003, 95: 134-143. 10.1159/000074840.CrossRef
44.
go back to reference Cinar M, Ulker S, Alper G, Evinc A: Effect of dietary vitamin E supplementation on vascular reactivity of thoracic aorta in streptozotocin-diabetic rats. Pharmacology. 2001, 62 (1): 56-64. 10.1159/000056072.CrossRefPubMed Cinar M, Ulker S, Alper G, Evinc A: Effect of dietary vitamin E supplementation on vascular reactivity of thoracic aorta in streptozotocin-diabetic rats. Pharmacology. 2001, 62 (1): 56-64. 10.1159/000056072.CrossRefPubMed
45.
go back to reference Obrosova I, Fathallah L, Greene D: Early changes in lipid peroxidation and antioxidative defense in rat retina. Eur J Pharm. 2000, 398: 139-146. 10.1016/S0014-2999(00)00286-7.CrossRef Obrosova I, Fathallah L, Greene D: Early changes in lipid peroxidation and antioxidative defense in rat retina. Eur J Pharm. 2000, 398: 139-146. 10.1016/S0014-2999(00)00286-7.CrossRef
46.
go back to reference Kocak G, Aktan F, Canbolat O, Ozogul C, Elberg S, Yildizoglu-Ari N, Karasu C: Alpha-lipoic acid treatment ameliorates metabolic parameters, blood pressure, vascular reavtivity and morphology of vessels already damaged by streptozotocin-diabetes. Diab Nutr Metab. 2000, 13: 308-318. Kocak G, Aktan F, Canbolat O, Ozogul C, Elberg S, Yildizoglu-Ari N, Karasu C: Alpha-lipoic acid treatment ameliorates metabolic parameters, blood pressure, vascular reavtivity and morphology of vessels already damaged by streptozotocin-diabetes. Diab Nutr Metab. 2000, 13: 308-318.
47.
go back to reference Rauscher F, Sanders R, Watkins JI: Effects of coenzyme Q10 treatment on antioxidant pathways in normal and streptozotocin-induced diabetic rats. J Biochem Mol Toxicol. 2001, 15: 41-46. 10.1002/1099-0461(2001)15:1<41::AID-JBT5>3.0.CO;2-Z.CrossRefPubMed Rauscher F, Sanders R, Watkins JI: Effects of coenzyme Q10 treatment on antioxidant pathways in normal and streptozotocin-induced diabetic rats. J Biochem Mol Toxicol. 2001, 15: 41-46. 10.1002/1099-0461(2001)15:1<41::AID-JBT5>3.0.CO;2-Z.CrossRefPubMed
48.
go back to reference Maritim A, Sanders R, Watkins JI: Effects of alpha-lipoic acid on biomarkers of oxidative stress in streptozotic-induced diabetic rats. J Nutr Biochem. 2003, 14 (5): 288-294. 10.1016/S0955-2863(03)00036-6.CrossRefPubMed Maritim A, Sanders R, Watkins JI: Effects of alpha-lipoic acid on biomarkers of oxidative stress in streptozotic-induced diabetic rats. J Nutr Biochem. 2003, 14 (5): 288-294. 10.1016/S0955-2863(03)00036-6.CrossRefPubMed
49.
go back to reference Brands MW, Bell TD, Gibson B: Nitric oxide may prevent hypertension early in diabetes by counteracting renal actions of superoxide. Hypertension. 2004, 43 (1): 57-63. 10.1161/01.HYP.0000104524.25807.EE.CrossRefPubMed Brands MW, Bell TD, Gibson B: Nitric oxide may prevent hypertension early in diabetes by counteracting renal actions of superoxide. Hypertension. 2004, 43 (1): 57-63. 10.1161/01.HYP.0000104524.25807.EE.CrossRefPubMed
50.
go back to reference Skyrme-Jones RA, O'Brien RC, Berry KL, Meredith IT: Vitamin E supplementation improves endothelial function in type I diabetes mellitus: a randomized, placebo-controlled study. J Am Coll Cardiol. 2000, 36 (1): 94-102. 10.1016/S0735-1097(00)00720-8.CrossRefPubMed Skyrme-Jones RA, O'Brien RC, Berry KL, Meredith IT: Vitamin E supplementation improves endothelial function in type I diabetes mellitus: a randomized, placebo-controlled study. J Am Coll Cardiol. 2000, 36 (1): 94-102. 10.1016/S0735-1097(00)00720-8.CrossRefPubMed
51.
go back to reference Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Keaney JF, Creager MA: Oral antioxidant therapy improves endothelial function in Type 1 but not Type 2 diabetes mellitus. Am J Physiol. 2003, 285 (6): H2392-2398. Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Keaney JF, Creager MA: Oral antioxidant therapy improves endothelial function in Type 1 but not Type 2 diabetes mellitus. Am J Physiol. 2003, 285 (6): H2392-2398.
52.
go back to reference Gaede P, Poulsen HE, Parving HH, Pedersen O: Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in Type 2 diabetic patients. Diabet Med. 2001, 18 (9): 756-760. 10.1046/j.0742-3071.2001.00574.x.CrossRefPubMed Gaede P, Poulsen HE, Parving HH, Pedersen O: Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in Type 2 diabetic patients. Diabet Med. 2001, 18 (9): 756-760. 10.1046/j.0742-3071.2001.00574.x.CrossRefPubMed
53.
go back to reference Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P: Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000, 342 (3): 154-160. 10.1056/NEJM200001203420302.CrossRefPubMed Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P: Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000, 342 (3): 154-160. 10.1056/NEJM200001203420302.CrossRefPubMed
54.
go back to reference Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000, 356 (9237): 1213-1218. 10.1016/S0140-6736(00)02783-5.CrossRefPubMed Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000, 356 (9237): 1213-1218. 10.1016/S0140-6736(00)02783-5.CrossRefPubMed
55.
go back to reference Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N Engl J Med. 2003, 348 (5): 383-393. 10.1056/NEJMoa021778.CrossRefPubMed Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N Engl J Med. 2003, 348 (5): 383-393. 10.1056/NEJMoa021778.CrossRefPubMed
56.
go back to reference Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A: Primary prevention of cardiovascular events with low-dose aspirin and Vitamin E in Type 2 diabetic patients: Results of the Primary Prevention Project (PPP) trial. Diabetes Care. 2003, 26 (12): 3264-3272.CrossRefPubMed Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A: Primary prevention of cardiovascular events with low-dose aspirin and Vitamin E in Type 2 diabetic patients: Results of the Primary Prevention Project (PPP) trial. Diabetes Care. 2003, 26 (12): 3264-3272.CrossRefPubMed
57.
go back to reference Lonn EM, Yusuf S, Dzavik V, Doris CI, Yi Q, Smith S, Moore-Cox A, Bosch J, Riley WA, Teo KK: Effects of ramipril and vitamin E on atherosclerosis : The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001, 103 (7): 919-925.CrossRefPubMed Lonn EM, Yusuf S, Dzavik V, Doris CI, Yi Q, Smith S, Moore-Cox A, Bosch J, Riley WA, Teo KK: Effects of ramipril and vitamin E on atherosclerosis : The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001, 103 (7): 919-925.CrossRefPubMed
58.
go back to reference Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B, Bosch J, Dagenais G, Mann JFE, Gerstein HC: Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: Results of the HOPE study and MICRO-HOPE substudy. Diabetes Care. 2002, 25 (11): 1919-1927.CrossRefPubMed Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B, Bosch J, Dagenais G, Mann JFE, Gerstein HC: Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: Results of the HOPE study and MICRO-HOPE substudy. Diabetes Care. 2002, 25 (11): 1919-1927.CrossRefPubMed
59.
go back to reference Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schutte K, Gries FA: Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995, 38 (12): 1425-1433. 10.1007/BF00400603.CrossRefPubMed Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schutte K, Gries FA: Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995, 38 (12): 1425-1433. 10.1007/BF00400603.CrossRefPubMed
60.
go back to reference Reljanovic M, Reichel G, Rett K, Lobisch M, Schuette K, Moller W, Tritschler HJ, Mehnert H: Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res. 1999, 31 (3): 171-179.CrossRefPubMed Reljanovic M, Reichel G, Rett K, Lobisch M, Schuette K, Moller W, Tritschler HJ, Mehnert H: Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res. 1999, 31 (3): 171-179.CrossRefPubMed
61.
go back to reference Ziegler D, Hanefeld M, Ruhnau K, Hasche H, Lobisch M, Schutte K, Kerum G, Malessa R: Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care. 1999, 22 (8): 1296-1301.CrossRefPubMed Ziegler D, Hanefeld M, Ruhnau K, Hasche H, Lobisch M, Schutte K, Kerum G, Malessa R: Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care. 1999, 22 (8): 1296-1301.CrossRefPubMed
62.
go back to reference Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H, Reichel G: Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care. 1997, 20 (3): 369-373.CrossRefPubMed Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H, Reichel G: Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care. 1997, 20 (3): 369-373.CrossRefPubMed
63.
go back to reference Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, Low PA, Nehrdich D, Novosadova M, O'Brien PC: The sensory symptoms of diabetic polyneuropathy are improved with {alpha}-Lipoic Acid: The SYDNEY Trial. Diabetes Care. 2003, 26 (3): 770-776.CrossRefPubMed Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, Low PA, Nehrdich D, Novosadova M, O'Brien PC: The sensory symptoms of diabetic polyneuropathy are improved with {alpha}-Lipoic Acid: The SYDNEY Trial. Diabetes Care. 2003, 26 (3): 770-776.CrossRefPubMed
64.
go back to reference Ziegler D, Nowak H, Kempler P, Vargha P, Low PA: Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004, 21 (2): 114-121. 10.1111/j.1464-5491.2004.01109.x.CrossRefPubMed Ziegler D, Nowak H, Kempler P, Vargha P, Low PA: Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004, 21 (2): 114-121. 10.1111/j.1464-5491.2004.01109.x.CrossRefPubMed
65.
go back to reference Dobrian AD, Davies MJ, Schriver SD, Lauterio TJ, Prewitt RL: Oxidative stress in a rat model of obesity-induced hypertension. Hypertension. 2001, 37 (2 Part 2): 554-560.CrossRefPubMed Dobrian AD, Davies MJ, Schriver SD, Lauterio TJ, Prewitt RL: Oxidative stress in a rat model of obesity-induced hypertension. Hypertension. 2001, 37 (2 Part 2): 554-560.CrossRefPubMed
66.
go back to reference Bagi Z, Koller A, Kaley G: PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes. Am J Physiol. 2004, 286 (2): H742-748. Bagi Z, Koller A, Kaley G: PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes. Am J Physiol. 2004, 286 (2): H742-748.
67.
go back to reference Fukui T, Noma T, Mizushige K, Aki Y, Kimura S, Abe Y: Dietary troglitazone decreases oxidative stress in early stage type II diabetic rats. Life Sci. 2000, 66 (21): 2043-2049. 10.1016/S0024-3205(00)00531-2.CrossRefPubMed Fukui T, Noma T, Mizushige K, Aki Y, Kimura S, Abe Y: Dietary troglitazone decreases oxidative stress in early stage type II diabetic rats. Life Sci. 2000, 66 (21): 2043-2049. 10.1016/S0024-3205(00)00531-2.CrossRefPubMed
68.
go back to reference lida KT, Kawakami Y, Suzuki M, Shimano H, Toyoshima H, Sone H, Shimada K, Iwama Y, Watanabe Y, Mokuno H: Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats. Am J Physiol. 2003, 284 (6): E1125-1130. lida KT, Kawakami Y, Suzuki M, Shimano H, Toyoshima H, Sone H, Shimada K, Iwama Y, Watanabe Y, Mokuno H: Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats. Am J Physiol. 2003, 284 (6): E1125-1130.
69.
go back to reference Wilson SH, Simari RD, Best PJ, Peterson TE, Lerman LO, Aviram M, Nath KA, Holmes DR, Lerman A: Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol. 2001, 21 (1): 122-128.CrossRefPubMed Wilson SH, Simari RD, Best PJ, Peterson TE, Lerman LO, Aviram M, Nath KA, Holmes DR, Lerman A: Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol. 2001, 21 (1): 122-128.CrossRefPubMed
70.
go back to reference Takayama T, Wada A, Tsutamoto T, Ohnishi M, Fujii M, Isono T, Horie M: Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor. Circ J. 2004, 68 (11): 1067-1075. 10.1253/circj.68.1067.CrossRefPubMed Takayama T, Wada A, Tsutamoto T, Ohnishi M, Fujii M, Isono T, Horie M: Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor. Circ J. 2004, 68 (11): 1067-1075. 10.1253/circj.68.1067.CrossRefPubMed
71.
go back to reference Haendeler J, Hoffmann J, Zeiher AM, Dimmeler S: Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation. 2004, 110 (7): 856-861. 10.1161/01.CIR.0000138743.09012.93.CrossRefPubMed Haendeler J, Hoffmann J, Zeiher AM, Dimmeler S: Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation. 2004, 110 (7): 856-861. 10.1161/01.CIR.0000138743.09012.93.CrossRefPubMed
72.
go back to reference Deakin S, Leviev I, Guernier S, James RW: Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol. 2003, 23 (11): 2083-2089. 10.1161/01.ATV.0000096207.01487.36.CrossRefPubMed Deakin S, Leviev I, Guernier S, James RW: Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol. 2003, 23 (11): 2083-2089. 10.1161/01.ATV.0000096207.01487.36.CrossRefPubMed
73.
go back to reference Touyz RM: Reactive oxygen species and angiotensin II signaling in vascular cells – implications in cardiovascular disease. Braz J Med Biol Res. 2004, 37 (8): 1263-1273. 10.1590/S0100-879X2004000800018.CrossRefPubMed Touyz RM: Reactive oxygen species and angiotensin II signaling in vascular cells – implications in cardiovascular disease. Braz J Med Biol Res. 2004, 37 (8): 1263-1273. 10.1590/S0100-879X2004000800018.CrossRefPubMed
74.
go back to reference Touyz RM, Schiffrin EL: Ang II-stimulated superoxide production is mediated via phospholipase D in human vascular smooth muscle cells. Hypertension. 1999, 34 (4 Pt 2): 976-982.CrossRefPubMed Touyz RM, Schiffrin EL: Ang II-stimulated superoxide production is mediated via phospholipase D in human vascular smooth muscle cells. Hypertension. 1999, 34 (4 Pt 2): 976-982.CrossRefPubMed
75.
go back to reference Berry C, Anderson N, Kirk AJ, Dominiczak AF, McMurray JJ: Renin angiotensin system inhibition is associated with reduced free radical concentrations in arteries of patients with coronary heart disease. Heart. 2001, 86 (2): 217-220. 10.1136/heart.86.2.217.PubMedCentralCrossRefPubMed Berry C, Anderson N, Kirk AJ, Dominiczak AF, McMurray JJ: Renin angiotensin system inhibition is associated with reduced free radical concentrations in arteries of patients with coronary heart disease. Heart. 2001, 86 (2): 217-220. 10.1136/heart.86.2.217.PubMedCentralCrossRefPubMed
76.
go back to reference Steinberg D, Witztum JL: Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis?. Circulation. 2002, 105 (17): 2107-2111. 10.1161/01.CIR.0000014762.06201.06.CrossRefPubMed Steinberg D, Witztum JL: Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis?. Circulation. 2002, 105 (17): 2107-2111. 10.1161/01.CIR.0000014762.06201.06.CrossRefPubMed
77.
go back to reference Cuzzocrea S, Riley DP, Caputi AP, Salvemini D: Antioxidant therapy: A new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev. 2001, 53 (1): 135-159.PubMed Cuzzocrea S, Riley DP, Caputi AP, Salvemini D: Antioxidant therapy: A new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev. 2001, 53 (1): 135-159.PubMed
78.
go back to reference Szabo C, Mabley JG, Moeller SM, Shimanovich R, Pacher P, Virag L, Soriano FG, Van Duzer JH, Williams W, Salzman AL: Part I: pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol Med. 2002, 8 (10): 571-580.PubMedCentralPubMed Szabo C, Mabley JG, Moeller SM, Shimanovich R, Pacher P, Virag L, Soriano FG, Van Duzer JH, Williams W, Salzman AL: Part I: pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol Med. 2002, 8 (10): 571-580.PubMedCentralPubMed
79.
go back to reference Kris-Etherton PM, Lichtenstein AH, Howard BV, Steinberg D, Witztum JL: Antioxidant vitamin supplements and cardiovascular disease. Circulation. 2004, 110 (5): 637-641. 10.1161/01.CIR.0000137822.39831.F1.CrossRefPubMed Kris-Etherton PM, Lichtenstein AH, Howard BV, Steinberg D, Witztum JL: Antioxidant vitamin supplements and cardiovascular disease. Circulation. 2004, 110 (5): 637-641. 10.1161/01.CIR.0000137822.39831.F1.CrossRefPubMed
Metadata
Title
Oxidative stress and the use of antioxidants in diabetes: Linking basic science to clinical practice
Authors
Jeanette Schultz Johansen
Alex K Harris
David J Rychly
Adviye Ergul
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2005
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-4-5

Other articles of this Issue 1/2005

Cardiovascular Diabetology 1/2005 Go to the issue